Insulet

Insulet Gross Profit/Assets

The Gross Profit to Assets Ratio of Insulet (PODD) as of Nov 20, 2026 is 60.80 %. In the previous year, Gross Profit to Assets Ratio was 46.82 % — a change of 29.86% (higher).

Gross Profit/Assets

60.80 %

YoY

29.86%

Last updated:

Gross Profit to Assets Ratio of Insulet is 2025 60.80 % . Gross Profit to Assets Ratio of Insulet was 2024 46.82 % . It decreases by 29.86% higher compared to the previous year.

The Insulet Gross Profit/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit/Assets
Date
Gross Profit/Assets
Jan 1, 2018
39.86 USD
Jan 1, 2019
42.02 USD
Jan 1, 2020
31.09 USD
Jan 1, 2021
36.71 USD
Jan 1, 2022
35.79 USD
Jan 1, 2023
44.81 USD
Jan 1, 2024
46.82 USD
Jan 1, 2025
60.80 USD
The Insulet Gross Profit/Assets history
YEARGross Profit/AssetsYoY
60.80 %+29.86%
46.82 %+4.48%
44.81 %+25.23%
35.79 %-2.51%
36.71 %+18.07%
31.09 %-26.02%
42.02 %+5.44%
39.86 %+17.45%
33.94 %-26.59%
46.23 %-4.57%
48.44 %+2.15%
47.42 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insulet stock

Gross Profit to Assets Ratio of Insulet is 60.80 % in 2025.

Gross Profit to Assets Ratio of Insulet changed from 46.82 % to 60.80 %, representing a 29.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit to Assets Ratio Insulet since 2006 – with annual values, charts, and detailed analysis.

Gross Profit/Assets measures how efficiently a company uses its assets to generate gross profit. Research shows it is a strong predictor of future stock returns.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Profit to Assets Ratio's Insulet with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Profit to Assets Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Profit to Assets Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Insulet

All Key Metrics — Insulet